Tab%25252520rizatriptan

# Rizatriptan ## Overview Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine. It acts via cranial vessel constriction and inhibition of neuropeptide release. It is available as a conventional tablet and an Orally Disintegrating Tablet (ODT). ## Primary Indications Acute treatment of migraine attacks with or without aura in adults and pediatric patients. ## Adult Dosing * **Initial Dose:** 5 mg or 10 mg as a single dose. * **Maximum Dose:** 30 mg in any 24-hour period. * **Redosing:** If the migraine returns, a second dose may be administered at least 2 hours after the initial dose. ## Pediatric Dosing * **Ages 6–17 years (Weight <40 kg):** 5 mg. * **Ages 6–17 years (Weight ≥40 kg):** 10 mg. * **Dosing Frequency:** Single dose only per 24 hours. Data regarding safety/efficacy of a second dose in children are limited; follow institutional guidelines. ## Dose Adjustments * **Patients on Propranolol:** Use 5 mg dose. Maximum 15 mg in 24 hours due to increased rizatriptan plasma concentrations. * **Renal/Hepatic Impairment:** No specific adjustment required; use with caution in severe hepatic impairment. ## Contraindications * History of ischemic heart disease, coronary artery vasospasm (Prinzmetal’s angina), or MI. * History of stroke or transient ischemic attack (TIA). * Peripheral vascular disease or ischemic bowel disease. * Uncontrolled hypertension. * Administration within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. * MAO-A inhibitor therapy (or within 2 weeks of discontinuation). ## Adverse Effects * **Common:** Paresthesia, dizziness, somnolence, fatigue, and dry mouth. * **Serious:** Coronary vasospasm, arrhythmias, myocardial infarction, serotonin syndrome (when used with other serotonergic agents), and medication-overuse headache. ## Key Drug Interactions * **MAO Inhibitors:** Risk of toxicity; avoid concurrent use. * **Propranolol:** Increases rizatriptan blood levels (see Dose Adjustments). * **SSRIs/SNRIs:** Increased theoretical risk of serotonin syndrome; monitor for altered mental status, autonomic instability, and neuromuscular hyperactivity. * **Ergot derivatives:** Increased risk of prolonged vasospastic reactions; wait 24 hours between doses. ## Monitoring * Monitor blood pressure periodically after the first dose in patients with cardiovascular risk factors. * Evaluate for signs of serotonin syndrome if combined with other serotonergic medications. * Assess frequency of use to prevent medication-overuse headache. ## Clinical Pearls * **ODT Administration:** The ODT formulation should be placed on the tongue and allowed to dissolve; intake of liquid is not required. * **Efficacy:** Effectiveness is not diminished by the presence of food, but onset of action may be delayed slightly compared to conventional tablets. * **Cardiovascular Safety:** The first dose should be administered in a medical setting for patients with risk factors for coronary artery disease (e.g., post-menopausal women, men >40, uncontrolled hypertension). *** *Disclaimer: This information is for educational purposes only. Verify all dosages, contraindications, and drug interactions against current institutional protocols, updated prescribing information, or standardized drug references (e.g., Lexicomp, UpToDate) before prescribing or administering medication.*